Humana Inc.는 저명한 건강과 웰빙 기업으로, 다양한 자회사들을 통해 미국 전역에서 사업을 운영합니다. 이 회사의 운영 구조는 Retail, Group and Specialty, Healthcare ...
Humana Inc(HUM) 주가는 3.5% 상승해 406.00달러를 기록했으며, GF Value™ 367.01달러 대비 10.6% 높은 수준으로 나타나 완만하게 과대평가된 것으로 시사됩니다. 87/100의 강한 GF Score™를 보였는데, 이는 뛰어난 성장 전망에 힘입은 결과입니다. 다만 재무 건전성은 보통이며 현재 P/E 비율은 역사적 중앙값보다 유의미하게 높습니다. 최근 3개월 동안 내부자 거래 활동이 없었으며, 이는 내부자 심리에 대해 여러 가지 방식으로 해석될 수 있습니다.
UnitedHealth Group(UNH)은 7월 16일 2026년 2분기 실적을 발표할 예정이며, 현재 실적 추정치는 주당 4.84달러, 매출은 1,100.5억 달러입니다. 회사 주가 성과는 연초 대비로 업종보다 약간 더 나은 편이지만, 밸류에이션은 5년 중앙값보다 높습니다. 이 글은 규제 조사와 가입자 감소 같은 과제에도 불구하고, UNH의 다각화된 플랫폼과 개선된 의료비용 관리가 긍정적인 요인이라고 설명하며, 다가오는 실적을 모니터링하면서 점진적으로 매수(누적)하는 방안을 투자자에게 권합니다.
UnitedHealth Group(UNH)은 2026년 2분기 실적을 발표할 준비를 하고 있으며, 주요 추정치는 주당순이익(EPS)이 18.6% 증가하지만 매출은 소폭 감소할 것으로 예측합니다. 일부 가입자 감소와 진행 중인 규제 조사가 있긴 하지만, 이 글은 UNH의 다각화된 플랫폼과 의료비용 관리가 수익성을 끌어올릴 수 있다고 제안합니다. 현재는 역사적 밸류에이션보다 높은 가격에 거래되고 있지만, 장기 성장 전망이 투자자에게 흥미로운 고려 대상이 된다는 점을 강조합니다.
Humana는 2028년까지 메디케어 어드밴티지 마진 3%를 목표로 하며, 가입자 성장에서 수익성으로 초점을 전환하고 있습니다. 회사는 현재 의료 이용률이 높은 것 같은 당면 과제에도 불구하고, 엄격한 가격 책정, 개선된 상품 설계, 더 나은 유지율(리텐션), 그리고 더 타이트한 케어 관리 등을 통해 이를 달성할 계획입니다. UnitedHealth Group과 CVS Health 같은 경쟁사들도 메디케어 어드밴티지 수익성을 우선시하고 있어, 유사한 전략을 통해 마진을 개선하려는 업계 전반의 흐름을 보여준다고 할 수 있습니다.
Humana(HUM)는 2028년까지 메디케어 어드밴티지 마진 3%를 목표로 하며, 회원 수 성장에 집중하던 방향에서 수익성으로 초점을 전환하고 있습니다. 회사는 의료 이용 증가와 규제 과제에도 불구하고, 엄격한 가격 책정, 제품 설계 개선, 회원 유지율 향상, 케어 관리 강화를 통해 이 목표를 달성할 계획입니다. UnitedHealth Group(UNH)과 CVS Health(CVS) 같은 동종 업체들도 메디케어 어드밴티지 수익성을 회복하기 위해 유사한 전략을 실행하고 있습니다.
Humana Inc(HUM) 주가는 3.5% 상승해 406.00달러를 기록했으며, GF Value™ 367.01달러 대비 10.6% 높은 수준으로 나타나 완만하게 과대평가된 것으로 시사됩니다. 87/100의 강한 GF Score™를 보였는데, 이는 뛰어난 성장 전망에 힘입은 결과입니다. 다만 재무 건전성은 보통이며 현재 P/E 비율은 역사적 중앙값보다 유의미하게 높습니다. 최근 3개월 동안 내부자 거래 활동이 없었으며, 이는 내부자 심리에 대해 여러 가지 방식으로 해석될 수 있습니다.
UnitedHealth Group(UNH)은 7월 16일 2026년 2분기 실적을 발표할 예정이며, 현재 실적 추정치는 주당 4.84달러, 매출은 1,100.5억 달러입니다. 회사 주가 성과는 연초 대비로 업종보다 약간 더 나은 편이지만, 밸류에이션은 5년 중앙값보다 높습니다. 이 글은 규제 조사와 가입자 감소 같은 과제에도 불구하고, UNH의 다각화된 플랫폼과 개선된 의료비용 관리가 긍정적인 요인이라고 설명하며, 다가오는 실적을 모니터링하면서 점진적으로 매수(누적)하는 방안을 투자자에게 권합니다.
UnitedHealth Group(UNH)은 2026년 2분기 실적을 발표할 준비를 하고 있으며, 주요 추정치는 주당순이익(EPS)이 18.6% 증가하지만 매출은 소폭 감소할 것으로 예측합니다. 일부 가입자 감소와 진행 중인 규제 조사가 있긴 하지만, 이 글은 UNH의 다각화된 플랫폼과 의료비용 관리가 수익성을 끌어올릴 수 있다고 제안합니다. 현재는 역사적 밸류에이션보다 높은 가격에 거래되고 있지만, 장기 성장 전망이 투자자에게 흥미로운 고려 대상이 된다는 점을 강조합니다.
Humana는 2028년까지 메디케어 어드밴티지 마진 3%를 목표로 하며, 가입자 성장에서 수익성으로 초점을 전환하고 있습니다. 회사는 현재 의료 이용률이 높은 것 같은 당면 과제에도 불구하고, 엄격한 가격 책정, 개선된 상품 설계, 더 나은 유지율(리텐션), 그리고 더 타이트한 케어 관리 등을 통해 이를 달성할 계획입니다. UnitedHealth Group과 CVS Health 같은 경쟁사들도 메디케어 어드밴티지 수익성을 우선시하고 있어, 유사한 전략을 통해 마진을 개선하려는 업계 전반의 흐름을 보여준다고 할 수 있습니다.
Humana(HUM)는 2028년까지 메디케어 어드밴티지 마진 3%를 목표로 하며, 회원 수 성장에 집중하던 방향에서 수익성으로 초점을 전환하고 있습니다. 회사는 의료 이용 증가와 규제 과제에도 불구하고, 엄격한 가격 책정, 제품 설계 개선, 회원 유지율 향상, 케어 관리 강화를 통해 이 목표를 달성할 계획입니다. UnitedHealth Group(UNH)과 CVS Health(CVS) 같은 동종 업체들도 메디케어 어드밴티지 수익성을 회복하기 위해 유사한 전략을 실행하고 있습니다.
Humana(HUM)는 웰스파고가 헬스 보험사를 Equal-Weight에서 Overweight으로 상향 조정한 뒤 주가가 2% 상승했습니다. 이번 상향 조정의 주요 근거는 메디케어 어드밴티지의 비용 추세가 완화되고 있다는 점이었습니다. 웰스파고는 또한 휴마나의 목표주가를 기존 227달러에서 502달러로 크게 상향했는데, 이는 현재 거래 가격 대비 약 28%의 상승 여력이 있음을 시사합니다.
CVS Health 주가는 52주 최고치 106.16달러를 기록했으며, 지난 1년간 64.76%의 상승과 66.66%의 총수익을 바탕으로 상당한 성장을 보여주고 있습니다. InvestingPro 분석에 따르면, 주식은 저평가 상태이며, GLP-1 지원 프로그램 확대와 Cantor Fitzgerald 및 BofA Securities 애널리스트의 목표주가 상향 등 최근의 전략적 조치가 이를 뒷받침합니다. 회사는 또한 주당 0.665달러의 분기 배당을 발표했습니다.
AMF Tjanstepension AB는 1분기 동안 Humana Inc. 지분을 2.9% 늘려, 현재 155,989주를 약 2,705만 달러 가치로 보유하고 있습니다. Humana는 EPS와 매출 추정치를 상회하는 등 강한 분기 실적을 발표했으며, 2026년 연간 가이던스를 상향 조정했습니다. 애널리스트들의 평가는 엇갈려 컨센서스가 'Hold' 등급이고 평균 목표주가가 303.74달러에 그치지만, 기관 투자자들은 주식의 92.38%를 보유하고 있습니다.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Humana Inc. (NYSE:HUM) for alleged corporate wrongdoing, specifically encouraging stockholders who purchased shares before June 27, 2022, and still hold them to join the investigation. The law firm represents investors in class actions on a contingency fee basis, aiming to restore investor capital and ensure corporate accountability.
Sumitomo Mitsui Trust Group Inc. reduced its stake in Humana Inc. by 8.4% in the first quarter, selling 29,651 shares and now owning 324,773 shares valued at approximately $56.3 million. Despite mixed analyst sentiment with an overall "Hold" rating, Humana exceeded quarterly earnings expectations, reporting an EPS of $10.31 on revenues of $39.65 billion, and announced a quarterly dividend of $0.885 per share. The company's stock traded down 1.3% on Friday, with a market capitalization of $47.16 billion.
ARGA Investment Management LP increased its stake in Humana Inc. by 3.1% in the first quarter, purchasing 7,013 additional shares to reach a total of 230,077 shares valued at $39.9 million. Despite a mixed "Hold" consensus rating from Wall Street analysts, Humana reported strong quarterly results with EPS of $10.31 and revenue of $39.65 billion, and declared a quarterly dividend of $0.885 per share. Institutional investors collectively own 92.38% of Humana's stock.
Centene Corporation's subsidiary, Meridian Health Plan of Illinois, has secured a four-year renewal of its contract under the state's HealthChoice Illinois Medicaid program, effective from January 1, 2027, through 2030. This renewal, while not expected to significantly boost near-term earnings, is critical for maintaining premium revenues and enhancing long-term earnings visibility for Centene, given its reliance on government-sponsored healthcare programs. The company's shares have rallied 64.3% year-to-date, outperforming the industry, and its 2026 earnings are projected to grow by 66.4%.
Humana Inc. (HUM) shares fell by 1.39% to $392.22 on Friday, ending a three-day winning streak, despite a positive trading session for the broader stock market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains.
UnitedHealth Group (UNH) is currently favored among managed care stocks due to its strong performance and positive outlook ahead of its July 16 earnings report. The company significantly beat Q1 2026 EPS expectations by nearly 10%, raised its 2026 guidance, and analysts predict a 71% probability of another Q2 beat. Unlike competitors like Humana and Elevance Health, UNH has demonstrated superior repricing discipline and medical care ratio, making it an attractive blue-chip income stock for investors.
Swedbank AB reduced its stake in Humana Inc. by 21.5% in the first quarter, now holding 87,741 shares valued at $15.21 million. Despite this, Humana reported strong quarterly results, beating EPS and revenue estimates, and declared a dividend of $0.885 per share; however, analysts maintain a "Hold" consensus rating with a $303.74 average price target. Other institutional investors have recently adjusted their positions in Humana, with a significant majority of the stock owned by institutions and hedge funds.
B. Riley Securities has reiterated LifeMD Inc. (NASDAQ: LFMD) as its top digital health stock to buy, maintaining a Buy rating and a $10 price target. The firm sees the recent sell-off as a buying opportunity, citing new catalysts including a telehealth collaboration with Antares, Medicare coverage for GLP-1 medications, and potential high-margin revenue from an FDA committee meeting. LifeMD also reported strong Q1 2026 financial results, surpassing analyst forecasts.
Humana (HUM) stock has seen a significant 69.8% return over the past year, leading to questions about its current valuation despite a recent win in the Illinois HealthChoice Medicaid program. The stock's current P/E ratio of 42.1x is higher than the sector and peer averages, though slightly below its Fair P/E Ratio of 44.6x. While the Illinois Medicaid expansion could boost long-term revenue, tightening Medicare scrutiny and the need for sustained earnings growth will determine if the current valuation is justified.
Humana Inc. (NYSE:HUM) has a consensus "Hold" rating from 28 analysts, with an average 1-year price target of $296.39. The company recently exceeded quarterly earnings expectations, reporting an EPS of $10.31 and revenue of $39.65 billion, a 23.5% increase year-over-year. Humana also declared a quarterly dividend of $0.885 per share, and institutional investors hold a significant 92.38% stake in the company.
HCA Healthcare, Inc. (NYSE:HCA) has received a "Moderate Buy" consensus rating from 24 brokerages, with an average 1-year price target of $497.14. Despite this positive overall outlook, several analysts recently lowered their price targets, indicating more cautious near-term expectations. The company reported Q1 earnings of $7.15 per share, slightly below estimates, while revenue exceeded forecasts at $19.11 billion, representing a 4.3% year-over-year increase.
The article highlights how uncertainty in Congressional control, particularly due to shifts in the Maine Senate race, impacts policy-sensitive companies in healthcare, pharmaceuticals, and clean energy. It discusses UnitedHealth Group (UNH), Pfizer (PFIZER), and NextEra Energy (NEE), detailing their exposure to potential regulatory changes, financial pressures, and political volatility, urging investors to consider these risks.
Shares of Alignment Healthcare (NASDAQ:ALHC) dropped 16.7% after a former executive filed a whistleblower lawsuit, alleging the company misreported expenses to inflate profits. The suit claims that reclassifying certain expenses would turn a positive adjusted EBITDA for 2024 into a loss. Alignment Healthcare denies the allegations, stating an independent audit found no basis for the claims, and the company plans to vigorously defend itself.
CF Industries has announced a 20% increase in its quarterly dividend, raising it to $0.60 per share. This dividend will be payable on August 31 to shareholders who are on record as of August 14. The move indicates confidence from the agricultural chemicals company regarding its financial performance and commitment to returning value to shareholders.
UnitedHealth Group (UNH) is investing $1.5 billion in AI initiatives for 2026, aiming to integrate AI across all its operations, including insurance, pharmacy, and care delivery, to simplify healthcare processes and improve user experience. The company expects these investments to streamline prior authorizations, accelerate prescription approvals, and enhance clinical productivity, extending beyond mere cost savings to strengthen customer relationships and expand software revenue. While competitors like Humana and Centene also leverage AI for efficiency, UNH's comprehensive approach positions it to reinforce its competitive standing in the digital healthcare industry.
Gartner (IT) experienced a decline in Q1 2026, leading to its shares falling 64.30% over the past 52 weeks, as reported by Artisan Mid Cap Value Fund. The company's core research business was affected by cyclical headwinds, including US government cost-cutting and longer sales cycles, with investor concerns also raised about the potential long-term impact of AI on its business model. Despite these challenges, Artisan Mid Cap Value Fund believes Gartner is attractively valued, citing its strong free cash flow, solid balance sheet, and capital returns to shareholders.
Gartner (NYSE:IT) experienced a significant decline in its stock price and was highlighted as a major decliner in Artisan Mid Cap Value Fund's Q1 2026 investor letter. The decline is attributed to signs of slowing growth and a weaker 2026 outlook, cyclical headwinds affecting its core research business, and investor concerns regarding AI's long-term impact. Despite these challenges, Artisan Mid Cap Value Fund believes Gartner is attractively valued, generates strong free cash flow, and has a solid balance sheet.
Humana Inc operates as a major US health insurer with a focus on Medicare Advantage and Medicaid, leveraging an aging population and government-funded programs. Its business model relies on efficient management of medical costs, risk adjustments, and adaptability to evolving health policies. The company also invests in health services capabilities and technology to manage care, control costs, and maintain a competitive edge.
UnitedHealth announced that an audit by FTI Consulting found nearly 97% of diagnoses made by its HouseCalls home-health unit in 2025 were supported by patient medical records. This comes after scrutiny from lawmakers and the Department of Health and Human Services regarding unsupported diagnoses impacting Medicare Advantage payments. The company acknowledges room for improvement in documentation practices.
Cantor Fitzgerald has increased its price target for Humana Inc. (NYSE:HUM) shares to $300 from $264, while maintaining a Neutral rating. This adjustment was made due to positive partial second-quarter 2026 Medicaid enrollment data, suggesting Humana is trending positively in enrollment growth. Despite the adjusted price target, Humana's current stock price of $392.86 is significantly higher, near its 52-week high, following a 68% gain over the past year.
This July 2026 update details regulatory and legislative changes impacting several key areas. It covers developments in gender identity discrimination under the ACA, FLSA overtime exemption standards, the ERISA status of "Trump Accounts," and recent antitrust settlements for Blue Cross Blue Shield. The update also includes information on PCORI fee reporting, Massachusetts MCC standards for 2027, and mid-year increases in Paid Family and Medical Leave benefits in certain states.
CMS is proposing to expand its authority to revoke Medicare provider privileges as part of an effort to crack down on healthcare fraud, waste, and abuse. The proposed rule would allow CMS to remove providers for additional reasons, including operating in areas with an "excessive" number of providers, convictions related to sexual assault or financial misconduct, or issues with owners' licenses in other states. These changes, part of the Calendar Year 2027 Home Health Prospective Payment System Proposed Rule, aim to save taxpayers an estimated $82 million annually while also updating home health payments with a 2.4% increase.
UnitedHealth Group is a major player in the U.S. healthcare sector, integrating insurance and health services. The company's diversified model and involvement in public programs like Medicare and Medicaid are key factors for investors evaluating its long-term growth prospects. Its ability to balance growth with cost management in a highly regulated industry is also a significant consideration.
UnitedHealth Group Incorporated continues to emphasize its diversified portfolio of health benefits and services. The company's dual structure as both an insurer and a services provider, combining commercial, Medicare, and Medicaid plans with pharmacy benefits and data analytics, is a key feature. Investors are closely monitoring membership trends, medical cost management, and the company's role in the broader U.S. healthcare system.
CVS Health has distinguished itself through strong management and strategic execution, outperforming peers despite industry challenges. The company reported a significant Q1 beat, anticipates margin expansion in 2026, and projects low double-digit investor returns. While its Health Services and Insurance segments are expected to grow, the retail segment will see gradual decline offset by improved margins, leading to a reiterated 'Buy' rating.
Cantor Fitzgerald has reiterated a Neutral rating on Humana Inc. (NYSE:HUM) with a $264 price target, despite the stock currently trading significantly higher. The firm noted Humana's strategic shift towards increased Medicaid exposure, highlighting recent enrollment changes in Kentucky and Louisiana, and mentioned the company's recent contract win in Illinois and sale of its stake in Gentiva. InvestingPro analysis suggests Humana is undervalued and has "GOOD" financial health.
Cantor Fitzgerald maintained a Neutral rating and a $264 price target for Humana (NYSE:HUM), despite the stock currently trading significantly higher at $396.75 and near its 52-week high. The firm highlighted Humana’s increased Medicaid exposure and its performance in Kentucky and Louisiana, where the company gained enrollment from a competitor's contract termination. InvestingPro analysis suggests Humana is undervalued with "GOOD" financial health.
Ambetter health plans by Centene Corp. are a major product line on the Affordable Care Act (ACA) marketplaces, providing essential health benefits to millions of US families. The plans offer tiered options (bronze, silver, gold), digital tools, and focus on affordability for individuals and families without employer-sponsored coverage. Ambetter's presence across many states and its integration with ACA subsidies make it a significant player in the national health insurance landscape, affecting both consumers and Centene's financial performance.
This article examines three large-cap multinational companies—Humana (HUM), Vishay Intertechnology (VSH), and Schneider National (SNDR)—that are positioned to benefit from major policy shifts, regulatory changes, and interest rate adjustments. Each company operates in sectors with significant catalysts, such as government-backed healthcare, electronics manufacturing, and logistics, offering potential for growth despite existing challenges like thin margins and debt-funded balance sheets. The analysis focuses on their market positioning, operational intricacies, and financial health to identify opportunities for investors.
Humana Inc. (NYSE: HUM) is navigating dynamic market conditions with a strong presence in the healthcare plans sector, boasting a $47.63 billion market capitalization and 23.50% revenue growth driven by its Insurance and CenterWell divisions. Despite mixed market sentiment and stock volatility, analysts anticipate continued earnings growth, supported by a healthy free cash flow and a modest dividend yield. While technical indicators suggest a bullish phase, the discrepancy between the current price and target prices emphasizes the need for thorough analysis of market conditions for investors.
Molina Healthcare specializes in government-sponsored health plans, primarily focusing on Medicaid, Medicare, and Affordable Care Act (ACA) marketplaces. The company operates as a managed care organization, contracting with state agencies to provide health benefits to vulnerable populations, emphasizing care coordination and cost control. Its business model, which includes a diversified portfolio of government-related health plans, is attractive to investors interested in publicly funded healthcare.
Jim Cramer expressed positive sentiment towards CVS Health Corporation, predicting that its recent gains will be long-lasting. He highlighted the company's strong performance in its latest quarter, including an earnings beat and a raised full-year forecast, which led to a 7.7% stock increase and a three-year high. Cramer also sees value in other health insurers like UnitedHealth and Humana.
Deutsche Bank has released its top investment ideas for the third quarter of 2026, known as its "Fresh Money" list, which includes 41 stocks across various sectors. The list has historically outperformed the S&P 500. Noteworthy picks include Oracle for its AI cloud leadership, Starbucks for its turnaround potential, and AppLovin for its unique scaled internet asset.
This article provides the latest SEC filing information and comprehensive financial data for Humana Inc. (HUM). It details various financial metrics such as market cap, income, sales, P/E ratios, dividend information, and performance indicators, alongside insider ownership and institutional transactions. The data reflects the company's financial health and stock performance as of July 2, 2024.
CVS Health Corp. is expanding its integrated healthcare model, combining pharmacy, insurance, and clinical services to achieve long-term stability in the evolving U.S. healthcare landscape. The company's diversified approach, spanning retail pharmacies, pharmacy benefit management, and health insurance, aims to create a comprehensive care ecosystem. Investors are evaluating how effectively this integrated structure can translate into resilient earnings and improved patient outcomes through coordinated care.
Strs Ohio has reduced its holdings in CVS Health Corporation by 13.4% in the first quarter, now owning 769,277 shares valued at approximately $55.25 million. Despite this reduction, Wall Street analysts maintain a "Moderate Buy" rating for CVS, with a consensus target price of $101.28. The company recently reported strong quarterly results, surpassing earnings and revenue estimates, and raised its full-year 2026 EPS guidance.
Fideuram Intesa Sanpaolo Private Banking S.P.A. increased its stake in CVS Health Corporation by 28.6% in the first quarter, purchasing an additional 32,077 shares. Institutional investors collectively own 80.66% of CVS Health's stock, though several insider sales by EVP Tilak Mandadi and Director Larry Robbins were also reported. Analysts generally forecast growth for CVS Health, with a consensus "Moderate Buy" rating and an average target price of $101.28.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Humana Inc. (NYSE: HUM) for alleged corporate wrongdoing. The firm is encouraging shareholders who purchased Humana securities before June 27, 2022, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, seeking to recover investor capital and ensure corporate accountability.
Humana Inc. director Kurt J. Hilzinger was granted 233 Restricted Stock Units (RSUs) on June 30, 2026, as a compensation-related equity award, with a reference price of $392.32 per share. Following this transaction, he directly holds 19,448 shares of Humana common stock and 16,534 RSUs. These RSUs and deferred stock units, which arise from annual director fees, cash fee conversions, and dividend reinvestments, are payable in Humana common stock upon his resignation from the board.
Humana Inc (HUM) shares recently dropped 3.1% to $396.75, yet the stock is still considered overvalued according to its GF Value™ estimate. Despite a strong GF Score™ of 86/100, driven by growth and momentum, the company's financial strength and valuation raise concerns for investors. There has been no insider trading activity in the last three months, suggesting a stable internal outlook on the company's direction.
Elevance Health has filed a lawsuit against the Centers for Medicare and Medicaid Services (CMS) regarding the recalculation of the 2026 Medicare Advantage star ratings. The CMS plans to redo these star ratings for all insurance providers. The article highlights other related news in politics and regulation, including HHS freezing New York's Medicaid fraud unit funds and CMS proposing changes to hospital outpatient pay and 340B cuts.
Humana Inc. (HUM) stock underperformed on Thursday, dropping 3.09% to $396.75. This occurred during a mixed trading session where the S&P 500 Index remained largely unchanged and the Dow Jones Industrial Average rose. The stock's decline ended a six-day winning streak.
